Mon-Fri 9am-5pm (EST)
Our scientific advisors include individuals accomplished in the fields of advanced cell and molecular imaging, computational biology, gastrointestinal medicine, comparative effectiveness research, and diagnostic test development.
Dr. Inadomi is a Cyrus E. Rubin Professor of Medicine and Head, Division of Gastroenterology, at the University of Washington School of Medicine. Dr. Inadomi received an undergraduate degree in biomechanical engineering from M.I.T. and an M.D. from the University of California, San Francisco. He has been on the faculty of the University of New Mexico, the University of Michigan, and the University of California, San Francisco, where he was the Dean M. Craig Endowed Chair in Gastrointestinal Medicine. Dr. Inadomi was recruited to UW Medicine in 2010 to become the fourth head of the Division of Gastroenterology in the Department of Medicine.
Dr. Inadomi is a gastroenterologist with expertise in comparative effectiveness research. He has received funding from the National Institutes of Health (NIH) to evaluate new techniques to decrease mortality from esophageal adenocarcinoma, and to test novel interventions to increase adherence to colorectal cancer screening tests. He is currently the chair of the American Gastroenterological Association Clinical Practice and Quality Management Committee, senior associate editor of the American Journal of Gastroenterology, a member of the American Board of Internal Medicine Subspecialty Board in Gastroenterology, and a standing member of the NIH Health Services, Organization and Delivery Study Section.
Robert F. Murphy is the Ray and Stephanie Lane Professor of Computational Biology and Director (Department Head) of the Ray and Stephanie Lane Center for Computational Biology in the School of Computer Science at Carnegie Mellon University. He also is Professor of Biological Sciences, Biomedical Engineering, and Machine Learning, and was a founding director (with Ivet Bahar) of the Joint Carnegie Mellon University-University of Pittsburgh Ph.D. Program in Computational Biology.
Dr. Murphy has received research grants from the National Institutes of Health, the National Science Foundation, the American Cancer Society, the American Heart Association, the Arthritis Foundation, and the Rockefeller Brothers Fund. He has co-edited two books and three special journal issues on cell imaging, and has published over 180 research papers. He is Past-President of the International Society for Advancement of Cytometry, was named as the first External Senior Fellow of the School of Life Sciences in the Freiburg (Germany) Institute for Advanced Studies, and has been named as an Honorary Professor at the University of Freiburg. He is a member of the National Advisory General Medical Sciences Council and the National Institutes of Health Council of Councils. Dr. Murphy's career has centered on combining fluorescence-based cell measurement methods with quantitative and computational methods. Dr. Murphy received an A.B. in Biochemistry from Columbia College and a Ph.D. in Biochemistry from the California Institute of Technology.
Lans Taylor is currently Director of the Drug Discovery Institute and Allegheny Foundation Professor of Computational & Systems Biology at the University of Pittsburgh. As Director of the Drug Discovery Institute, he works with both academic and commercial collaborators to discover and develop efficacious and safe therapeutics based on the integration of outstanding science, technology and drug discovery/development methods.
Dr. Taylor is a co-founder and scientific advisor to Cernostics, starting the company based on the vision of applying systems biology approaches to fundamental tissue diagnostics and anatomic pathology. Prior to founding Cernostics, Dr. Taylor founded multiple life science companies including Biological Detection Systems (acquired by Amersham), Cellomics (acquired by ThermoFisher), and Cellumen. Dr. Taylor holds more than 25 U.S. patents, including six focused on cell-based imaging. His academic career has included positions at Harvard University and Carnegie Mellon University, where he was awarded multiple accolades for his work including a NIH MERIT award from 1990-2000 and a Pioneer Award from the National Science Foundation.
Dr. Warrington has more than 25 years' experience in biotechnology, devices, and diagnostics R&D. Prior to joining Centrillion Biosciences, Janet was Co-Founder and Senior Vice President at Second Genome Inc., where she built the organization, a network of laboratories, and the leadership team. Before founding Second Genome, Janet helped build Affymetrix from a small start-up to a multi-billion dollar market cap corporation, serving in a variety of roles including Vice President, Research and Development, Molecular Diagnostics. In partnership with Roche Molecular Systems, Dr. Warrington was the originator and lead scientist for the first FDA cleared microarray system for a diagnostic test. Janet has been awarded over $75 million in public and private funding, holds several patents, and has published more than 60 scientific papers and book chapters. She serves as an advisor to Cernostics, Second Genome, and the Bioengineering Department, Santa Clara University.
Dr. Warrington earned her Ph.D. in Biological Chemistry from UC Irvine, and was a Department of Energy supported postdoctoral scholar in genetics at Stanford University.
Dr. Kornblith is a neurosurgeon, academic, inventor, and entrepreneur. He trained at Temple University, Jefferson Medical College, the University of Pennsylvania, and Massachusetts General Hospital. He was formerly a faculty member at Harvard University, Chief of Surgical Neurology at the NIH, Professor of Neurosurgery and Chairman at Albert Einstein College of Medicine, and Professor of Neurosurgery and Vice Chairman at the University of Pittsburgh.
While at NIH, his work led to the development of innovative chemosensitivity assays, and he also served as leader of the NIH PET program, discovering its value in clinical cancer management. In 1995, he founded and served as President and CEO of Precision Therapeutics, Inc., a cancer chemoresponse company. Presently, Dr. Kornblith is Adjunct Professor at the University of Pittsburgh School of Health and Rehabilitation Sciences. He is the Western Pennsylvania Regional Director for PABiotech.
Mon-Fri 9am-5pm (EST)